## SANTA CRUZ BIOTECHNOLOGY, INC.

# PBEF (F-8): sc-393510



## BACKGROUND

Pre-B cell-enhancing factor (PBEF), also designated nicotinamide phosphoribosyltransferase (Nampt) or visfatin, belongs to the NAPRTase family of proteins. PBEF may be involved in enhancing the effect of IL-7 and SCF on the formation of early B-lineage precursor colonies. It is involved in the catalysis of nicotinamide with 5-phosphoribosyl-1-pyrophosphate, yielding nicotinamide mononucleotide, which is important in NAD biosynthesis. This is a rate limiting step in the NAD biosynthesis pathway. Highly enriched in the visceral fat of both human and mouse, PBEF expression levels in plasma increase during the development of obesity. PBEF is a cytoplasmic protein expressed primarily in bone marrow, muscle and liver tissue, but it can also be detected in placenta, lung, kidney and heart tissue.

## REFERENCES

- 1. Samal, B., et al. 1994. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14: 1431-1437.
- Ognjanovic, S., et al. 2001. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J. Mol. Endocrinol. 26: 107-117.

## **CHROMOSOMAL LOCATION**

Genetic locus: NAMPT (human) mapping to 7q22.3; Nampt (mouse) mapping to 12 A3.

#### **SOURCE**

PBEF (F-8) is a mouse monoclonal antibody raised against amino acids 1-300 mapping at the N-terminus of PBEF of human origin.

## PRODUCT

Each vial contains 200  $\mu g\, lg G_1$  kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## **APPLICATIONS**

PBEF (F-8) is recommended for detection of PBEF of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for PBEF siRNA (h): sc-45843, PBEF siRNA (m): sc-45844, PBEF shRNA Plasmid (h): sc-45843-SH, PBEF shRNA Plasmid (m): sc-45844-SH, PBEF shRNA (h) Lentiviral Particles: sc-45843-V and PBEF shRNA (m) Lentiviral Particles: sc-45844-V.

Molecular Weight of PBEF: 52 kDa.

Positive Controls: HL-60 whole cell lysate: sc-2209,  $BC_3H1$  cell lysate: sc-2299 or HeLa whole cell lysate: sc-2200.

#### **RECOMMENDED SUPPORT REAGENTS**

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>™</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850. 4) Immunohistochemistry: use m-IgGκ BP-HRP: sc-516102 with DAB, 50X: sc-24982 and Immunohistomount: sc-45086, or Organo/Limonene Mount: sc-45087.

#### DATA





PBEF (F-8): sc-393510. Western blot analysis of PBEF expression in HL-60 (A), HeLa (B), Sol8 (C), BC<sub>3</sub>H1 (D) and L6 (E) whole cell lysates and mouse postnatal heart tissue extract (F).

PBEF (F-8): sc-393510. Immunofluorescence staining of methanol-fixed HeLa cells showing nuclear and cytoplasmic localization (**A**). Immunoperoxidase staining of formalin fixed, paraffin-embedded human bone marrow tissue showing nuclear and cytoplasmic staining of hematopoietic cells (**B**).

#### SELECT PRODUCT CITATIONS

- Mpilla, G., et al. 2019. PAK4-NAMPT dual inhibition as a novel strategy for therapy resistant pancreatic neuroendocrine tumors. Cancers 11: 1902.
- Mpilla, G.B., et al. 2021. PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus. Mol. Cancer Ther. 20: 1836-1845.

## **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.